S&P/ASX 200 Index (ASX: XJO) shares are up 0.16% to 8,810.5 points on Monday.
Among the 11 market sectors, energy is in the lead today, up 1.9%.
The technology sector is the laggard, down 1.1%.
Let's check out some new ratings on three ASX 200 shares.
Image source: Getty Images
Wisetech Global Ltd (ASX: WTC)
The Wisetech share price is $33.88, down 3.1% today and down 71% over 12 months.
Bell Potter has a buy rating on this ASX 200 tech share with a 12-month target price of $71.75.
Analyst Chris Savage said:
There has been a tech rally of sorts on the ASX over the past couple of months and this has been led by some of the large cap names including Pro Medicus Ltd (ASX: PME), Block CDI (ASX: XYZ) and Life360 Inc (ASX: 360).
One large cap which has not rallied, however, is WiseTech and this is likely due to a number of factors including further negative press reports around founder and Chief Innovation Officer Richard White, concern around the potential future loss of key customer DSV and risk around both the FY26 result and FY27 guidance and whether each meets market expectations.
In our view, however, these negatives will start to dissipate over the coming months and indeed have already commenced with
the appointment earlier this month of Raelene Murphy to Chair which we regard as a positive move.
Sigma Healthcare Ltd (ASX: SIG)
The Sigma Healthcare share price is $2.94, up 0.2% today and up 7% over 12 months.
Bell Potter has a hold rating on this ASX 200 healthcare share with a price target of $3.
Analyst John Hester said:
… investment metrics for SIG are not sufficiently attractive to warrant a Buy rating, particularly with a single payer (the Federal Government) representing a disproportionate level of group revenue.
The Government's propensity to alter funding arrangements on short notice with little industry consultation should elevate the risk rating on SIG.
Commonwealth Bank of Australia (ASX: CBA)
CBA shares are $172.73 apiece, up 0.6% today and down 3% over 12 months.
Morgans has a sell rating on CBA shares and just reduced its 12-month target from $119.40 to $117.63.
Analyst Nathan Lead said:
We make updates to our forecasts ahead of the FY26 result in August. Net result is 1-2% downgrades to FY27-28F EPS.
Sell retained, given stretched valuation metrics remain implied in the share price (c.26x PER, 3.7x PBV, 2.9% cash yield).
